Verastem (NASDAQ:VSTM) received a significant boost as BTIG Research upgraded its rating to a “strong-buy” in a note issued to investors on March 5, 2024. This positive assessment comes amidst a flurry of activity from various research firms evaluating the biopharmaceutical company.
Several firms have recently commented on Verastem’s stock. Jefferies Financial Group reaffirmed a “buy” rating and set a price target of $19.00 per share. Meanwhile, HC Wainwright initiated coverage with a “buy” rating and a target price of $18.00. In contrast, Weiss Ratings maintained a “sell (d-)” rating as of January 21, 2024. Overall, three analysts rated the stock as a Strong Buy, five gave it a Buy rating, one rated it as Hold, and one analyst issued a Sell rating. According to data from MarketBeat.com, Verastem has an average rating of “Buy” and an average target price of $16.83.
Recent Financial Performance and Insider Activity
Verastem recently reported its quarterly earnings results on March 4, 2024, revealing an earnings per share (EPS) of ($0.50). This figure fell short of analysts’ consensus estimates of ($0.49) by $0.01. The company recorded revenue of $17.54 million for the quarter, exceeding expectations of $16.85 million. Analysts predict that Verastem will post an EPS of ($3.02) for the current year.
In terms of insider activity, CEO Dan Paterson sold 10,321 shares on January 12, 2024, at an average price of $7.16, totaling $73,898.36. Following this transaction, he retained 400,104 shares, valued at approximately $2.86 million. Chief Financial Officer Daniel Calkins also sold shares, offloading 5,039 shares on the same day for a total of $36,079.24. Insiders collectively sold 17,678 shares worth $128,685 over the last ninety days and hold 2.10% of the company’s stock.
Institutional Investor Interest
Recent activity among institutional investors indicates growing interest in Verastem. Polar Capital Holdings Plc increased its stake by 270.7% in the fourth quarter, now holding 3,925,126 shares valued at $30.3 million after acquiring an additional 2,866,350 shares. Other notable investments include Armistice Capital LLC, which purchased a new stake worth $8.86 million, and Farallon Capital Management LLC, which invested $15.44 million in the fourth quarter.
Overall, institutional investors control 88.37% of Verastem’s stock, reflecting strong confidence in the company’s future.
Verastem Oncology, a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, focuses on developing small molecule therapies targeting cancer stemness and resistance pathways. Their lead product, COPIKTRA (duvelisib), is an oral inhibitor of PI3K-delta and PI3K-gamma, emphasizing the company’s commitment to advancing cancer treatment.
As interest grows and ratings shift, Verastem remains a focal point in the biopharmaceutical sector, with numerous analysts and investors closely monitoring its developments.
